Skip to content
PubMed This is a summary of 96 peer-reviewed journal articles Updated
Hematology · Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP): A Patient Guide

At a Glance

Primary immune thrombocytopenia (ITP) is an autoimmune condition that lowers platelets by increasing their destruction and reducing production. Diagnosis requires ruling out other causes, and care focuses on preventing serious bleeding with safe counts and appropriate monitoring.

Primary Immune Thrombocytopenia (ITP) is an autoimmune condition that fundamentally changes how your body maintains its supply of platelets, the small cells responsible for blood clotting. In a healthy system, platelets are produced in the bone marrow and circulate in the blood until they are needed to seal a wound. For someone living with ITP, the immune system mistakenly identifies these platelets as targets, leading to a “double hit” where the body both destroys existing platelets too quickly and fails to produce enough new ones to replace them [1][2].

Because there is no single test that can definitively “prove” you have ITP, the path to a diagnosis is often a process of elimination. Your care team works to evaluate important alternative causes for a low platelet count, such as infections, certain medications, or other underlying health conditions, until no secondary cause is currently identified after an appropriate evaluation [3]. This period of testing can be an emotional time, especially if your counts are very low, but it is an essential step in ensuring that your treatment is tailored specifically to your body’s needs.

The way ITP behaves can vary significantly depending on when and in whom it is diagnosed. In children, the condition is often a temporary response to a viral infection, frequently resolving on its own without the need for intensive medication [4]. In adults, however, ITP is more likely to become a chronic, long-term companion that requires ongoing monitoring. Regardless of age, the modern goal of care has shifted away from chasing a “normal” blood count and toward achieving a “safe” or hemostatic count—a level high enough to prevent serious bleeding while minimizing the side effects of treatment [5].

Living with ITP means learning to balance the clinical data of blood tests with the reality of how you feel day-to-day. While a low platelet count increases the risk of bruising or bleeding, most people find that with the right management strategy, they can lead full and active lives. By focusing on safety and quality of life rather than just the numbers on a lab report, you and your medical team can navigate the challenges of ITP with confidence and a clear plan for the future [6].

What to Do Now

If you are newly diagnosed, keep these three things in mind today:

  1. Know your numbers and symptoms: Keep a record of your most recent platelet count and any active bleeding.
  2. Know when to get urgent help: Call your local emergency number if you experience severe headaches, neurological changes, a severe head injury, or uncontrolled bleeding.
  3. Check your medications: Do not take over-the-counter NSAIDs (like ibuprofen or naproxen) or aspirin without checking with your hematologist, as these can interfere with platelet function.

Common questions in this guide

What is primary immune thrombocytopenia (ITP)?
Primary ITP is an autoimmune condition in which the immune system mistakenly attacks platelets, the blood cells that help stop bleeding. The body may also make too few new platelets, so people can bruise or bleed more easily.
How do doctors diagnose primary ITP?
There is no single test that proves primary ITP. Doctors review blood counts and evaluate other possible causes of low platelets, such as infections, medicines, or other health conditions; primary ITP is considered when no secondary cause is identified after appropriate evaluation.
What is a safe platelet count for someone with ITP?
Your safe target is the platelet level your care team considers high enough to reduce serious bleeding risk; it may not be the same as a normal count. The target depends on your symptoms, bleeding, health needs, and treatment plan, so your hematologist should interpret the number in context.
When is bleeding with ITP an emergency?
Call your local emergency number for uncontrolled bleeding, a severe headache, neurological changes, or a severe head injury. These warning signs need urgent assessment rather than waiting for the next appointment.
Can I take ibuprofen, naproxen, or aspirin with ITP?
Do not take over-the-counter NSAIDs such as ibuprofen or naproxen, or aspirin, without first checking with your hematologist. These medicines can interfere with platelet function, so your clinician needs to decide whether they are safe for you.
Does primary ITP go away, or is it lifelong?
ITP can follow different courses. In children it often occurs after a viral infection and resolves on its own, while in adults it is more likely to persist and require long-term monitoring; an individual's course cannot be predicted from age alone.
Why might my doctor recommend monitoring instead of immediate ITP treatment?
Watchful waiting is a care approach in which platelet counts and symptoms are monitored before active treatment. Whether it is appropriate depends on your bleeding risk, platelet count, and overall clinical situation, and the plan may change if those factors change.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on primary thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific symptoms and blood work, what makes you confident this is 'primary' rather than 'secondary' ITP?
  2. 2.What is my personal 'safe' platelet target, and how does that differ from a 'normal' count?
  3. 3.What are the first steps we will take to ensure my treatment is as targeted and low-toxicity as possible?
  4. 4.How often will we need to monitor my counts during this initial phase, and what would trigger a change in our plan?

References

References (6)
  1. 1

    Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.

    Audia S, Mahévas M, Nivet M, et al.

    HemaSphere 2021; (5(6)):e574 doi:10.1097/HS9.0000000000000574.

    PMID: 34095758
  2. 2

    Pathogenesis of immune thrombocytopenia.

    Audia S, Mahévas M, Samson M, et al.

    Autoimmunity reviews 2017; (16(6)):620-632 doi:10.1016/j.autrev.2017.04.012.

    PMID: 28428120
  3. 3

    Update on diagnosis and treatment of immune thrombocytopenia.

    Sandal R, Mishra K, Jandial A, et al.

    Expert review of clinical pharmacology 2021; (14(5)):553-568 doi:10.1080/17512433.2021.1903315.

    PMID: 33724124
  4. 4

    Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants.

    Bennett CM, Neunert C, Grace RF, et al.

    Pediatric blood & cancer 2018; (65(1)) doi:10.1002/pbc.26736.

    PMID: 28792679
  5. 5

    Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

    Choi PY, Merriman E, Bennett A, et al.

    The Medical journal of Australia 2022; (216(1)):43-52 doi:10.5694/mja2.51284.

    PMID: 34628650
  6. 6

    Second-line therapies in immune thrombocytopenia.

    Grace RF, Neunert C

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):698-706 doi:10.1182/asheducation-2016.1.698.

    PMID: 27913549

This page is for informational purposes only and does not constitute medical advice. It explains primary ITP and safety concerns, but your hematologist should guide decisions about symptoms, medications, monitoring, and treatment.